malignant lymphoma or multiple myeloma
Conditions
Interventions
Intervention: Use of GFO and lactobacillus in patients who receive autologous PBSCT
Standard : No Use of GFO and lactobacillus in patients who receive autologous PBSCT
Sponsors
National Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Malignant lymphoma or multiple myeloma who can be candidate for autologous PBSCT (2) 17<Age<66 (3) ECOG PS <2 (4) No obvious organ failure (5) They have given written informed consent (6) Patients who will survive more than 3 months
Exclusion criteria
Exclusion criteria: (1) History of stem cell transplantation (2) HIV carrier (3) Uncontrolled active infectious diseases (4) Pregnant or lactating (5) Uncontrolled psychological disorder(6) Allergy for the drugs used for the conditioning regimen (7) Allergy for GFO or lactobacillus (8) Patients who do not tolerate the maximal defined conditioning regimen due to organ dysfunction (e.g., reduce MCNU due to pulmonary dysfunction, reduce Carboplatin due to renal dysfunction)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Probability of more than grade 3 intestinal regimen related toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) 1-year overall survival and event-free survival (2) Regimen related toxicity except intestinal toxicity (3) Engraftment (4) Infectious diseases (5) Duration of TPN (6) Dose and duration of intravenous morphine (7) Dose of insulin (8) Hyperglycemia and hypoglycemia (9) DAO activity | — |
Countries
Japan
Contacts
Public ContactShigeo Fuji
NTT West Japan Osaka Hospital Department of Hematology
Outcome results
None listed